Real-Time PCR Assays for the Quantification of HCV RNA: Concordance,Discrepancies and Implications for Response Guided Therapy |
| |
| Authors: | Robert Strassl Karoline Rutter Albert Friedrich St?ttermayer Sandra Beinhardt Michael Kammer Harald Hofer Peter Ferenci Theresia Popow-Kraupp |
| |
| Affiliation: | 1. Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria.; 2. Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Vienna, Austria.; 3. Center for Medical Statistics, Informatics, and Intelligent Systems (CeMSIIS), Medical University of Vienna, Vienna, Austria.; University of the Witwatersrand, SOUTH AFRICA, |
| |
| Abstract: | Background and AimsMonitoring of chronic Hepatitis C (CHC) treatment relies on HCV RNA quantification by means of real-time PCR methods. Assay specific analytical sensitivities may impact therapy management.MethodsComparative analysis between three commercial assays (Roche COBAS AmpliPrep/COBAS TaqMan Version 1 (CAP/CTM Ver. 1), Version 2 (CAP/CTM Ver. 2) and the Abbott RealTime HCV (ART) assay) was performed on 247 available samples taken at key decision time points during antiviral therapy of 105 genotype 1 patients (triple therapy: n = 70; dual therapy: n = 35).ResultsOverall concordance of HCV RNA measurements was high between the two Roche systems (89%; n = 220/247) but lower between the Roche assays and the ART (CAP/CTM Ver. 1 vs ART: 77.3%; n = 191/247 and CAP/CTM v.2 vs ART: 80.1%; n = 198/247). Most discrepancies were noted in week 4/8 samples with residual viremia (ConclusionAn abbreviated course of treatment can safely be applied in patients with residual viremia (
|
| |
| Keywords: | |
|
|
